The Motley Fool··Eric VolkmanSi-Bone Stock Surges 20% on Strong Q1 Earnings and FDA Clearance
$SIBN rallied nearly 20% after reporting 11% revenue growth, narrowing losses, and securing FDA approval for its iFuse INTRA Ti implant system.
SIBNrevenue growthguidance raise